Comparison Workspace
Program Compare
Compare up to 6 HearScape records side by side across ownership, modality, stage, evidence, populations, trials, source support, and review notes.
1 Selected Records
URL-shareable comparison set.
| Field | Otarmeni by Regeneron Regeneron Pharmaceuticals |
|---|---|
| Organization | Company: Regeneron Pharmaceuticals |
| Program Type | Therapeutic |
| Modality | Gene Therapy |
| Stage / Status | Approved / Approved |
| Review Status | checked · regulatory |
| Confidence | 99% |
| Target / Gene | OTOF |
| Route / Mode | Intracochlear infusion |
| Indications | Hearing Loss; Sensorineural Hearing Loss; Genetic Hearing Loss; OTOF-Related Hearing Loss; Auditory Neuropathy |
| Population Tags | pediatric; adult; congenital; genetic; otof-dfnb9; pre-lingual; bilateral; profound |
| Geography | United States; European Union; United Kingdom; Spain |
| Trials | |
| Source Support | 3 structured sources · 3 URL-backed · regulatory, company, clinicaltrials |
| Last Reviewed | 2026-05-31 |
| Data Checks | No data flags |
| Mechanism | Dual-AAV intracochlear gene replacement delivers functional OTOF to cochlear inner hair cells to restore otoferlin-mediated auditory signaling. |
| Notes | Field-defining OTOF program; transitioned from Decibel to Regeneron after the 2023 acquisition and became the first approved gene therapy for genetic hearing loss in 2026. |